Patents by Inventor Ernst Weber

Ernst Weber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11180770
    Abstract: In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: November 23, 2021
    Assignee: BASF Agricultural Solutions Seed US LLC
    Inventors: Marc Linka, Fabien Poree, Bernd Laber, Gudrun Lange, Christina Thies, Ernst Weber, Michael Strerath, Sandra Geske, Heike Balven-Ross, Nina Wobst, Wayne Coco, Nikolaus Pawlowski, Jan Tebbe, Manuel Dubald
  • Patent number: 11071788
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: July 27, 2021
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Hans-Georg Lerchen, Anne-Sophie Rebstock, Yolanda Cancho Grande, Sven Wittrock, Sandra Berndt, Uwe Gritzan, Jenny Fitting, Beatrix Stelte-Ludwig, Patrick Jones, Christoph Mahlert, Christian Votsmeier, Dorian Schönfeld, Mark Trautwein, Ernst Weber, Nikolaus Pawlowski, Simone Greven, Julian Marius Glück, Stefanie Hammer, Lisa Dietz, Stephan Märsch
  • Publication number: 20210139555
    Abstract: The present invention relates to an antibody or a fragment thereof comprising at least one heterologous amino acid sequence incorporated within at least one CDR region of said antibody or fragment thereof, wherein said at least one heterologous amino acid sequence comprises an N-terminal linker sequence (Nils), an Atrial Natriuretic Peptide (ANP) and a C-terminal linker sequence (Ctls). Optionally, at least a portion of said at least one CDR region is replaced by said at least one heterologous amino acid sequence incorporated therein. The present invention further relates to such antibody or fragment thereof for use in a method for treatment, a composition comprising such antibody or fragment thereof, a nucleic acid or a mixture of nucleic acids encoding such antibody or fragment thereof, a host cell comprising such nucleic acid or such mixture of nucleic acids and to a process for producing such antibody or fragment thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: May 13, 2021
    Applicant: Bayer Aktiengesellschaft
    Inventors: Anke MAYER-BARTSCHMID, Damian BROCKSCHNIEDER, Marcel GEERTZ, Simone GREVEN, Lucas Hudson HOFMEISTER, Hannah JÖRISSEN, Christoph MAHLERT, Tobias MARQUARDT, Ilka MATHAR, Thomas MONDRITZKI, Claudia NOACK, Jan TEBBE, Stuart WALSH, Ernst WEBER, Andreas WILMEN, Frank WUNDER
  • Publication number: 20200332013
    Abstract: Bispecific antibodies binding ALK-1 and BMPR-2 The present invention relates to bispecific antibodies binding human ALK-1 and human BMPR-2. Also provided are BsABs which are agonists of ALK-1/BMPR-2 signaling, and BsABs which do not trigger osteogenic signaling. Furthermore, the invention relates to pharmaceutical uses of the BsABs, in particular for the treatment of pulmonary hypertension. Also provided are methods to screen for BsABs for use in the therapy, e.g. of pulmonary hypertension.
    Type: Application
    Filed: October 25, 2018
    Publication date: October 22, 2020
    Inventors: Ernst Weber, Joerg Meding, Florian Sohler, Julian Marius Glueck
  • Publication number: 20200239905
    Abstract: In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 30, 2020
    Applicant: BASF Agricultural Solutions Seed US LLC
    Inventors: Marc Linka, Fabien Poree, Bernd Laber, Gudrun Lange, Ernst Weber, Michael Strerath, Sandra Geske, Heike Balven-Ross, Nina Wobst, Wayne Coco, Nikolaus Pawlowski, Jan Tebbe, Christina Thies, Manuel Dubald
  • Publication number: 20200138970
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: May 7, 2020
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Sandra BERNDT, Uwe GRITZAN, Jenny FITTING, Beatrix STELTE-LUDWIG, Patrick JONES, Christoph MAHLERT, Christian VOTSMEIER, Dorian SCHÖNFELD, Mark TRAUTWEIN, Ernst WEBER, Nikolaus PAWLOWSKI, Simone GREVEN, Julian Marius GLÜCK, Stefanie HAMMER, Lisa DIETZ, Stephan MÄRSCH
  • Patent number: 10597674
    Abstract: In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: March 24, 2020
    Assignee: BASF Agricultural Solutions Seed, US LLC
    Inventors: Marc Linka, Fabien Poree, Bernd Laber, Gudrun Lange, Jan Tebbe, Wayne Coco, Michael Strerath, Ernst Weber, Nikolaus Pawlowski, Sandra Geske, Heike Balven-Ross, Nina Wobst, Christina Thies, Manuel Dubald
  • Publication number: 20200063155
    Abstract: In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Application
    Filed: March 1, 2018
    Publication date: February 27, 2020
    Applicant: BASF Agricultural Solutions Seed US LLC
    Inventors: Marc Linka, Fabien Poree, Bernd Laber, Gudrun Lange, Christina Thies, Ernst Weber, Michael Strerath, Sandra Geske, Heike Balven-Ross, Nina Wobst, Wayne Coco, Nikolaus Pawlowski, Jan Tebbe, Manuel Dubald
  • Publication number: 20190298865
    Abstract: The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a methyl group, and a coupling moiety terminating in a carboxylic acid group; b) coupling said octadentate chelator to at least one tissue-targeting moiety targeting prolyl endopeptidase FAP; and c) contacting said tissue-targeting chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treatment of a neoplastic or hyperplastic disease comprising administration of such a tissue-targeting thorium complex, as well as the complex and corresponding pharmaceutical formulations are also provided.
    Type: Application
    Filed: June 6, 2017
    Publication date: October 3, 2019
    Applicants: BAYER PHARMA AKTIENGESELLSCHAFT, BAYER AS
    Inventors: Alan CUTHBERTSON, Mark TRAUTWEIN, Ernst WEBER, Jenny KARLSSON, Stefanie HAMMER
  • Publication number: 20180208937
    Abstract: In the present invention, HPPD polypeptides and plants containing them showing a full tolerance against one or more HPPD inhibitor herbicides belonging to various chemical classes are described. A set of mutant HPPD polypeptides have been designed which have either no or only a significantly reduced affinity to HPPD inhibitor herbicides and, at the same time, the rate of dissociation of the HPPD inhibitors of the mutant HPPD polypeptide is increased to such an extent that the HPPD inhibitors no longer act as slow-binding or slow, tight-binding inhibitors but, instead of this, have become fully reversible inhibitors. In particular, isolated polynucleotides encoding mutant HPPD polypeptides conferring tolerance to HPPD inhibitor herbicides belonging to various chemical classes are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed.
    Type: Application
    Filed: September 8, 2016
    Publication date: July 26, 2018
    Inventors: Marc Linka, Fabien POREE, Bernd LABER, Gudrun LANGE, Jan TEBBE, Wayne COCO, Michael STRERATH, Ernst WEBER, Nikolaus PAWLOWSKI, Sandra GESKE, Heike BALVEN-ROSS, Nina WOBST, Christina THIES, Manuel DUBALD
  • Publication number: 20180185510
    Abstract: The present application relates to novel binder drug conjugates (ADCs), to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for the treatment and/or prophylaxis of diseases and to the use of these ADCs for preparing medicaments for treatment and/or prophylaxis of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: June 20, 2016
    Publication date: July 5, 2018
    Inventors: Hans-Georg LERCHEN, Anne-Sophie REBSTOCK, Yolanda CANCHO GRANDE, Sven WITTROCK, Uwe GRITZAN, Pedro PAZ, Melanie FISCHER, Juergen FRANZ, Julian Marius GLÜCK, Stephan MÄRSCH, Beatrix STELTE-LUDWIG, Christoph MAHLERT, Ernst WEBER, Simone GREVEN, Sandra BERNDT
  • Publication number: 20170369889
    Abstract: System for producing a nucleic acid construct of interest, said system comprising: a set of n entry DNAs numbered 1 to n, n being an integer of at least 2, each of said n entry DNAs comprising in this order: (i) a type IIs restriction endonuclease recognition site followed by the cleavage site thereof; (ii) a sequence portion linking the cleavage site of said recognition site of item (i) with the cleavage site of the recognition site of the following item (iii), and (iii) a cleavage site of a further type IIs restriction endonuclease recognition site followed by the recognition site of said cleavage site; the cleavage sites of the type IIs restriction endonuclease recognition sites of item (iii) of entry DNAs 1 to n?1 are complementary to the cleavage sites of the type IIs restriction endonuclease recognition sites of item (i) of entry DNAs 2 to n, respectively; the cleavage site of the type IIs restriction endonuclease recognition site of item (iii) of entry DNA n is complementary to the cleavage site of
    Type: Application
    Filed: June 27, 2017
    Publication date: December 28, 2017
    Applicant: Icon Genetics GmbH
    Inventors: Ernst Weber, Stefan Werner, Carola Engler, Ramona Grutzner, Sylvestre Marillonnet
  • Patent number: 8883420
    Abstract: A process of inserting a nucleic acid sequence of interest into an acceptor nucleic acid is provided. The process comprises amplifying by PCR a DNA comprising in the following order a sequence segment U, a nucleic acid sequence segment of known nucleotide sequence K2, and a nucleic acid sequence segment of known sequence K3. The process further comprises treating the linear double-stranded DNA molecules from the PCR amplification with an exonuclease to obtain a single-stranded overhang at the first end of the DNA and a single-stranded overhang comprising nucleic acid segments K2 and K3 at the second end of the DNA. The process additionally comprises annealing the product of the exonuclease treatment to a linearized double-stranded acceptor nucleic acid which has been designed to complement the single-stranded overhangs of the product of the exonuclease treatment.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: November 11, 2014
    Assignee: Icon Genetics GmbH
    Inventors: Sylvestre Marillonnet, Stefan Werner, Carola Engler, Romy Kandzia, Frank Thieme, Ernst Weber
  • Publication number: 20130267021
    Abstract: System for producing a nucleic acid construct of interest, said system comprising: a set of n entry DNAs numbered 1 to n, n being an integer of at least 2, each of said n entry DNAs comprising in this order: (i) a type IIs restriction endonuclease recognition site followed by the cleavage site thereof; (ii) a sequence portion linking the cleavage site of said recognition site of item (i) with the cleavage site of the recognition site of the following item (iii), and (iii) a cleavage site of a further type Ms restriction endonuclease recognition site followed by the recognition site of said cleavage site; the cleavage sites of the type IIs restriction endonuclease recognition sites of item (iii) of entry DNAs 1 to n?1 are complementary to the cleavage sites of the type IIs restriction endonuclease recognition sites of item (i) of entry DNAs 2 to n, respectively; the cleavage site of the type Ms restriction endonuclease recognition site of item (iii) of entry DNA n is complementary to the cleavage site of the t
    Type: Application
    Filed: June 9, 2011
    Publication date: October 10, 2013
    Applicant: ICON GENETICS GMBH
    Inventors: Ernst Weber, Stefan Werner, Carola Engler, Ramona Grützner, Sylvestre Marillonnet
  • Publication number: 20110263024
    Abstract: A process of inserting a nucleic acid sequence of interest into an acceptor nucleic acid, comprising the following steps: amplifying by PCR a DNA comprising in the following order a sequence segment U, a nucleic acid sequence segment of known nucleotide sequence K2 and a nucleic acid sequence segment of known sequence K3 using a forward primer defining a first end of the amplified DNA and a reverse primer defining a second end of the amplified DNA, said reverse primer terminating at its 3?-end in a nucleotide sequence of nucleic acid sequence segment K3; treating the linear double-stranded DNA molecules contained in the PCR product obtained in the previous step with an exonuclease to obtain a single-stranded overhang at the first end of the DNA and a single-stranded overhang comprising nucleic acid segments K2 and K3 at the second end of the DNA; and annealing the product of the previous step to a linearized double-stranded acceptor nucleic acid having at a first end thereof a single-stranded overhang comp
    Type: Application
    Filed: October 8, 2009
    Publication date: October 27, 2011
    Applicant: ICON GENETICS GmbH
    Inventors: Sylvestre Marillonnet, Stefan Werner, Carola Engler, Romy Kandzia, Frank Thieme, Ernst Weber
  • Publication number: 20040152627
    Abstract: The present invention relates to pharmaceutical compositions containing a synergistic amount of at least one bone morphogenetic protein (BMP) and a synergistic amount of at least one pyrrolidone optionally in a pharmaceutically acceptable carrier, such as a biodegradable polymer. The present invention further relates to methods of treating orthopaedic and dental, including periodontal, diseases by simultaneously administering a synergistic amount of at least one bone morphogenetic protein (BMP) and a synergistic amount of at least one pyrrolidone optionally in a pharmaceutically acceptable carrier to patients in need of such treatment.
    Type: Application
    Filed: January 30, 2003
    Publication date: August 5, 2004
    Applicant: The University of Zurich
    Inventor: Franz Ernst Weber
  • Patent number: 4927544
    Abstract: A three or optionally four stage process for the continuous removal of a gum phase from triglyceride oil is described in which in a first stage the oil containing a separate gum phase is subjected to centrifugal separation in a first centrifugal separator to yield gums with low oil content and an oil that still contains a fraction of the gums originally present in the feed, in a second stage the oil obtained from the first stage is subjected to centrifugal separation in a second centrifugal separator to yield oil with a further reduced residual gum content and a gum phase with a higher oil content than the gums obtained in the first stage, in a third stage the gum phase obtained in the second stage is recycled into the oil stream fed to the first centrifugal separator and optionally in a fourth stage the oil obtained in the second stage is washed one or more times with water.
    Type: Grant
    Filed: March 14, 1989
    Date of Patent: May 22, 1990
    Assignee: N.V. Vandemoortele International
    Inventors: Martin van Opstal, Frans Dewulf, Bernard Cleenewerck, Ernst Weber
  • Patent number: 4735014
    Abstract: (a) The invention relates to a method of and an apparatus for industrially growing particularly mushrooms and also to a substrate used for such cultivation.(b) A method characterized in that a substrate is used which consists of a mixture based on hemp stalks, the substrate being prepared by impregnation in water, whereupon the substrate is fixed on supports constituting vertical walls, whereupon the apparatus (1) carrying the substrate is placed in an incubation room and then in a growing room.(c) The present invention has its main application in the mushrooms growing industry.
    Type: Grant
    Filed: May 19, 1986
    Date of Patent: April 5, 1988
    Assignee: Weber Development Engineering SA
    Inventor: Ernst Weber